520 results on '"Seynaeve, C."'
Search Results
2. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
3. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial
4. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
5. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
6. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
7. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands
8. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients
9. Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline
10. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
11. Relevant impact of central pathology review on nodal classification in individual breast cancer patients
12. Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction
13. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
14. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
15. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
16. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors
17. Psychological Distress and Breast Self-Examination Frequency in Women at Increased Risk for Hereditary or Familial Breast Cancer
18. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients
19. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
20. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
21. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer
22. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?
23. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
24. COPD in cancer patients: Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient
25. Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy
26. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy
27. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations
28. Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing
29. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
30. Survival and prognostic factors in BRCA1-associated breast cancer
31. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study
32. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
33. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries
34. The Distress Thermometer assessed in women at risk of developing hereditary breast cancer
35. Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study
36. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
37. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer
38. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
39. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
40. A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours
41. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2 *1100delC variant
42. Controlling cancer chemotherapy-induced emesis: An update
43. Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear
44. 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
45. Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer
46. Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk
47. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
48. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
49. 9P Long term recurrence risk predictions by CanAssist breast in a sub-cohort of TEAM trial
50. Imaging surface and submembranous structures with the atomic force microscope: a study on living cancer cells, fibroblasts and macrophages
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.